ASIA MABRY: Open Payments
NPI 1730954199 · GOLDSBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,415 in 213 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $1,444 · 2025 $3,415
Food & beverage: $3,304Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 43 | $501 |
| ABBVIE INC. | 35 | $479 |
| E.R. Squibb & Sons, L.L.C. | 18 | $393 |
| Vanda Pharmaceuticals Inc. | 19 | $356 |
| Otsuka America Pharmaceutical, Inc. | 20 | $304 |
| Alkermes, Inc. | 16 | $246 |
| Axsome Therapeutics, Inc. | 9 | $239 |
| Lundbeck LLC | 9 | $186 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $183 |
| Neurocrine BioSciences, Inc. | 13 | $178 |
Products named: VRAYLAR, REXULTI, COBENFY, HETLIOZ, ARISTADA, Auvelity, AUSTEDO XR, CAPLYTA.
Industry payments across NC — which companies pay providers there.
